Vaporox, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$255Kgeneral payments (2019-2025)
$32Kresearch payments (2019-2025)
246clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Vht-200 Wound Treatment System $113K associated (2023-2025)
- Vht-200 $24K associated (2023-2025)
- Vht-200 Wound Treatment Device $254 associated (2023-2025)
- Vht-200 Wound Treatment Systme $167 associated (2023-2025)
- Vht-200 Wound Care System $126 associated (2023-2025)
- Vh-200 Wound Treatment System $98.02 associated (2023-2025)
- Vht-200 Wound Treatment System $52.88 associated (2023-2025)
- Vht-200 Wound Treatment Center $32.43 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Dustin Kruse | Wheat Ridge, CO | Foot & Ankle Surgery | $153,859.27 |
| Paul Kesselman | Oceanside, NY | Foot & Ankle Surgery | $23,790.46 |
| Kenneth Morgan | Denver, CO | Podiatrist | $16,649.42 |
| Michael Duehrssen | Lincoln, NE | Emergency Medicine | $11,429.53 |
| David Armstrong | Los Angeles, CA | Podiatrist | $10,000.00 |
| Jeremy Christensen | Castle Rock, CO | Podiatrist | $6,462.93 |
| Jason Harrill | Mesa, AZ | Foot & Ankle Surgery | $1,155.98 |
| Yehia Elebrashi | Peoria, AZ | Foot & Ankle Surgery | $875.89 |
| Traci Kimball | Arvada, CO | Surgery | $741.20 |
| Sergio Zamora | Eagle Pass, TX | Family Medicine | $589.97 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.